GlobeNewswire
VR Farms Out its Copper-Nickel-PGM Properties in Ontario, and Dials in Exploration and Drill Planning in Nevada
VANCOUVER, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSXV: VRR) is pleased to announce that i...
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership
PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with me...
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patie...
Calian and ADGA Group Sign Collaborative Agreement to Advance Next-Generation Land Training and Simulation for the Canadian Army
Collaboration will deliver collective training designed and delivered to meet today’s modern battlefield and Canada’s defence modernization priorities...
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –...
Kyivstar Group Board Members Visit Ukraine on the Fourth Anniversary of the Full-Scale War
KYIV, Ukraine, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Members of the Board of Directors of Kyivstar Group Ltd (“Kyivstar Group”; Nasdaq: KYIV;KYIVW), the...
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA cleara...
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for s...
Aeluma to Participate in 38th Annual ROTH Conference
GOLETA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable te...
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
Presentation showcases how Amphista’s Eclipsys® platform is enabling the development of Targeted Glue™ degraders, which recruit diverse E3 ligases, de...
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01...